» Articles » PMID: 35322391

Questionnaire and Tools: Clinical Powerful Instrument in Acromegaly Diagnosis and Management

Overview
Publisher Springer
Specialty Endocrinology
Date 2022 Mar 24
PMID 35322391
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Acromegaly is a rare chronic disease characterized by systemic comorbidity and reduced quality of life. Although achieving biochemical control has always been the primary goal of acromegaly therapy, recent evidence has shown that the traditional assessment does not adequately capture the complexity of symptoms and patients' perception. These findings result in the need to improve a fast decision-making process of the clinician, who should not only take into account biochemical-instrumental criteria, but also patients' symptoms. With the aim of supporting the clinician in the diagnostic and therapeutic decision-making process several disease-specific tools have been developed. The aim of this review is to provide a description of the acromegaly-specific tools, presenting their main features, their application in daily practice, and their efficacy and utility.

Methods: A systematic search of Medline/PubMed, ISI-Web of Knowledge, and Google Scholar databases was done.

Results: Specific instruments and questionnaires have recently been developed to assist clinicians in the assessment of acromegaly. These are either Patient-Reported Outcome tools, such as Acromegaly Quality of Life Questionnaire (AcroQoL) and Pain Assessment Acromegaly Symptom Questionnaire (PASQ), or Clinician-Reported Outcome tools, such as ACROSCORE, SAGIT and Acromegaly Disease Activity Tool (ACRODAT). Such tools are extremely flexible and, therefore, have been widely adopted by endocrinologists and other professionals, so much so that they have also been included as recommendations in the 2018 international guidelines.

Conclusion: Questionnaires and tools are useful in the management of acromegaly patients. They help clinicians evaluate patients' symptoms and could assist in the evaluation of disease activity.

Citing Articles

Patient perspectives on acromegaly disease burden: insights from a community meeting.

Shah S, Yuen K, Bonert V, Huang W, Sisco J, Palaty C Front Endocrinol (Lausanne). 2025; 16:1516131.

PMID: 39963277 PMC: 11830622. DOI: 10.3389/fendo.2025.1516131.


Acromegaly: diagnostic challenges and individualized treatment.

Freda P Expert Rev Endocrinol Metab. 2025; 20(1):63-85.

PMID: 39757391 PMC: 11832332. DOI: 10.1080/17446651.2024.2448784.


Shared decision-making and detection of comorbidities in an online acromegaly consultation with and without the Acromegaly Disease Activity Tool ACRODAT using the simulated person approach.

Friedel A, Schock L, Siegel S, Fritz A, Unger N, Harbeck B Pituitary. 2024; 27(5):545-554.

PMID: 39320650 PMC: 11513722. DOI: 10.1007/s11102-024-01460-6.


Validating evidence for the knowledge, management and involvement of dentists in a dental approach to sickle-cell disease.

Ancillotti L, de Abreu M, Marinho A, Santos M Braz Oral Res. 2024; 38:e026.

PMID: 38597546 PMC: 11376614. DOI: 10.1590/1807-3107bor-2024.vol38.0026.

References
1.
Dichtel L, Kimball A, Yuen K, Woodmansee W, Haines M, Guan Q . Effects of growth hormone receptor antagonism and somatostatin analog administration on quality of life in acromegaly. Clin Endocrinol (Oxf). 2020; 94(1):58-65. PMC: 9217182. DOI: 10.1111/cen.14309. View

2.
Liu S, Adelman D, Xu Y, Sisco J, Begelman S, Webb S . Patient-centered assessment on disease burden, quality of life, and treatment satisfaction associated with acromegaly. J Investig Med. 2017; 66(3):653-660. DOI: 10.1136/jim-2017-000570. View

3.
Wang K, Guo X, Yu S, Gao L, Wang Z, Zhu H . Mapping of the acromegaly quality of life questionnaire to ED-5D-5L index score among patients with acromegaly. Eur J Health Econ. 2021; 22(9):1381-1391. DOI: 10.1007/s10198-021-01318-9. View

4.
Guaraldi F, Gori D, Beccuti G, Prencipe N, Giordano R, Mints Y . Usefulness of an ad hoc questionnaire (Acro-CQ) for the systematic assessment of acromegaly comorbidities at diagnosis and their management at follow-up. J Endocrinol Invest. 2016; 39(11):1277-1284. DOI: 10.1007/s40618-016-0476-y. View

5.
Webb S, Badia X, Lara Surinach N . Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study. Eur J Endocrinol. 2006; 155(2):269-77. DOI: 10.1530/eje.1.02214. View